Immunic Shares Climb After Private Placement Is Priced

Dow Jones

Feb 13

By Katherine Hamilton

Immunic shares jumped after the biotechnology company priced its private placement with gross proceeds of up to $400 million.

The stock gained 20% to $1.051 in pre-market trading Friday. Through the close, it was up 12% over the past three months.

Proceeds are expected to support Immunic's transition from a research and development-focused company into a fully-integrated commercial entity.

Immunic will issue an aggregate of about 229.1 million pre-funded warrants to purchase shares at a price of about 87 cents per warrant. It will also issue warrants to buy up to 229.1 million shares for 87 cents a share.

In the coming months, the company plans to complete its phase 3 trial of vidofludimus calcium for relapsing multiple sclerosis and start a phase 3 trial in primary progressive multiple sclerosis.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

February 13, 2026 08:41 ET (13:41 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2611150552"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2611150552\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2611150552?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 21:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611150552","market":"other","top_or_hot":-1,"title":"Immunic Shares Climb After Private Placement Is Priced","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Immunic shares jumped after the biotechnology company priced its private placement with gross proceeds of up to $400 million. \n</p>\n<p>\n  The stock gained 20% to $1.051 in pre-market trading Friday. Through the close, it was up 12% over the past three months. \n</p>\n<p>\n  Proceeds are expected to support Immunic's transition from a research and development-focused company into a fully-integrated commercial entity. \n</p>\n<p>\n  Immunic will issue an aggregate of about 229.1 million pre-funded warrants to purchase shares at a price of about 87 cents per warrant. It will also issue warrants to buy up to 229.1 million shares for 87 cents a share. \n</p>\n<p>\n  In the coming months, the company plans to complete its phase 3 trial of vidofludimus calcium for relapsing multiple sclerosis and start a phase 3 trial in primary progressive multiple sclerosis. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 13, 2026 08:41 ET (13:41 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immunic Shares Climb After Private Placement Is Priced</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunic Shares Climb After Private Placement Is Priced\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-13 21:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Immunic shares jumped after the biotechnology company priced its private placement with gross proceeds of up to $400 million. \n</p>\n<p>\n  The stock gained 20% to $1.051 in pre-market trading Friday. Through the close, it was up 12% over the past three months. \n</p>\n<p>\n  Proceeds are expected to support Immunic's transition from a research and development-focused company into a fully-integrated commercial entity. \n</p>\n<p>\n  Immunic will issue an aggregate of about 229.1 million pre-funded warrants to purchase shares at a price of about 87 cents per warrant. It will also issue warrants to buy up to 229.1 million shares for 87 cents a share. \n</p>\n<p>\n  In the coming months, the company plans to complete its phase 3 trial of vidofludimus calcium for relapsing multiple sclerosis and start a phase 3 trial in primary progressive multiple sclerosis. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 13, 2026 08:41 ET (13:41 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2611150552","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611150552","pubTimestamp":1770990060,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Immunic shares jumped after the biotechnology company priced its private placement with gross proceeds of up to $400 million.The stock gained 20% to $1.051 in pre-market trading Friday. Through the close, it was up 12% over the past three months.Proceeds are expected to support Immunic's transition from a research and development-focused company into a fully-integrated commercial entity.Immunic will issue an aggregate of about 229.1 million pre-funded warrants to purchase shares at a price of about 87 cents per warrant. It will also issue warrants to buy up to 229.1 million shares for 87 cents a share.In the coming months, the company plans to complete its phase 3 trial of vidofludimus calcium for relapsing multiple sclerosis and start a phase 3 trial in primary progressive multiple sclerosis.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IMUX":"Immunic, Inc."},"translate_title":"私募定价后免疫股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMUX":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Immunic shares jumped after the biotechnology company priced its private placement with gross proceeds of up to $400 million. \n\n\n  The stock gained 20% to $1.051 in pre-market trading Friday. Through the close, it was up 12% over the past three months. \n\n\n  Proceeds are expected to support Immunic's transition from a research and development-focused company into a fully-integrated commercial entity. \n\n\n  Immunic will issue an aggregate of about 229.1 million pre-funded warrants to purchase shares at a price of about 87 cents per warrant. It will also issue warrants to buy up to 229.1 million shares for 87 cents a share. \n\n\n  In the coming months, the company plans to complete its phase 3 trial of vidofludimus calcium for relapsing multiple sclerosis and start a phase 3 trial in primary progressive multiple sclerosis. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 13, 2026 08:41 ET (13:41 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}